FDA-cleared BVA technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care. Key Highlights Commercial Acceleration Daxor showcasing its next-ge
Daxor Corporation (DXR) — Live Session & Technical Brief
Updated Nov 16, 2026 8:07 PM ET · Prev Close $8.48
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-1.47%) in Medical Instruments & Supplies
Daxor Corporation (DXR) is trading within a tight intraday band at $8.36 (-1.47%, 0.16x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, DXR is trading in line with the S&P 500 (+0.44% alpha). 14-day RSI stands at 31.2, keeping momentum in a bearish regime.
FDA-cleared BVA technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care. Key Highlights Commercial Acceleration Daxor showcasing its next-ge
Price ($8.36) trades relative to 20-day SMA ($8.91) and 50-day SMA ($10.07).
Market & Sector Relative Strength
DXR trading in line with the S&P 500 (+0.44% alpha)Recent DXR Catalyst Headlines
Verified WireNew Clinical Studies Validate BVA Technology in High-Acuity Heart Failure Populations to Enhance Care Oak Ridge, Tn, Oct. 14, 2026 Globe Newswire -- Daxor Corporation Nasdaq DXR , the global leader in blood volume measur
Making its ASN debut, Daxor s BVA technology delivers precise volume measurement to optimize fluid management and improve complex kidney care. Key Highlights Commercial Presence Daxor exhibiting at Booth 390 during ASN K
FDA 510 k -cleared next-generation diagnostic platform delivers 3x faster results with 50 less blood, setting a new standard for data-driven heart failure management. Key Highlights Commercial Acceleration Daxor to featu
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $8.91 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (DXR)
BEARISH MA TRENDRetail & Crowd Sentiment
QuietStockTwits shows bullish sentiment for $DXR with one user predicting a strong performance. No recent news articles were found.
About Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the Bva-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical …
Get Instant DXR Catalyst Alerts
Receive an email alert when DXR triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversDXR Session & Catalyst FAQ
Why is DXR stock trading near flat today?
Daxor Corporation (DXR) is trading within a tight intraday band at $8.36 (-1.47%, 0.16x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, DXR is trading in line with the S&P 500 (+0.44% alpha). 14-day RSI stands at 31.2, keeping momentum in a bearish regime.
Is DXR stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.16x relative volume (low participation). Our multi-factor model currently rates DXR as HOLD. Review full valuation, quality, and timing signals on the DXR Buy or Sell Decision Brief →
What is DXR's intrinsic value and expected trading range?
At $8.36, DXR's modeled 1-to-3 session range is $8.04 – $8.68, with a key inflection level at $8.91 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the DXR Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for DXR?
RSI at 31.2 reflects soft below-midline momentum. DXR trades at $8.36 relative to its 20-day SMA ($8.91) and 50-day SMA ($10.07), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.